Company InnoCan Pharma Corporation

INNO

CA45783P5085

Pharmaceuticals

Market Closed - Canadian Securities Exchange Other stock markets 12:35:24 2026-01-16 pm EST			5-day change	1st Jan Change
8.000 ^CAD	-1.23%		0.00%	+19.40%

Jan. 02	InnoCan Pharma to List on NYSE American Next Week	MT
Jan. 02	Innocan Pharma Corp Brief: Anticipates Listing on NYSE American Stock Exchange with Concurrent Offering	MT

Business description: InnoCan Pharma Corporation

Innocan Pharma Corporation is an Israel-based company active in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, the Company aims to provide a safe, non-opioid chronic pain management solutions for both animals and humans. To achieve this aim, the Company developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, the Company develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan established a Joint Venture (BI Sky Global Ltd.) that focused on advanced, targeted online sales.

Sales by Activity: InnoCan Pharma Corporation

Fiscal Period: December	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)
Online Sales	-	-	-	13.55M	29.4M
Other Operations	-	-	-	109K	38K
Pharmaceuticals	8K	196K	2.56M	-	-

See all business segments

Geographical breakdown of sales: InnoCan Pharma Corporation

Fiscal Period: December	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)
United States	-	34K	2.42M	13.55M	29.4M
Rest of The World	-	41K	59K	109K	38K
United Kingdom	-	-	83K	-	-
Poland	-	60K	-	-	-
France	-	61K	-	-	-
Israel	8K	-	-	-	-

See all geographic segments

Executive Committee: InnoCan Pharma Corporation

Manager	Title	Age	Since
Nir Avram CTO	Chief Tech/Sci/R&D Officer	73	-
Iris Bincovich CEO	Chief Executive Officer	-	2018-05-30
Nelson Halpern DFI	Director of Finance/CFO	-	2019-02-19
Eyal Kalo CTO	Chief Tech/Sci/R&D Officer	-	2023-04-30
Roni Kamhi COO	Chief Operating Officer	-	2022-08-10

See INNOCAN PHARMA CORPORATION governance

Composition of the Board of Directors: InnoCan Pharma Corporation

Director	Title	Age	Since
Iris Bincovich CHM	Chairman	-	2025-06-30
Ralph Bossino BRD	Director/Board Member	-	2019-09-29
Joshua Lintern BRD	Director/Board Member	39	2019-09-29
Eyal Flom BRD	Director/Board Member	61	2019-09-24
Peter Bloch BRD	Director/Board Member	66	2020-01-21
Roni Kamhi BRD	Director/Board Member	-	-

Composition of the Board of Directors

Shareholders: InnoCan Pharma Corporation

Name	Equities	%	Valuation
Solsken Ltd. 17.01 %	765,039	17.01 %	5 M $
Ron Abraham Mayron 2.306 %	103,746	2.306 %	740 746 $
Iris Bincovich 1.841 %	82,826	1.841 %	591 378 $
Eyal Flom 0.9339 %	42,014	0.9339 %	299 980 $
Roni Kamhi 0.228 %	10,257	0.228 %	73 235 $

List of INNOCAN PHARMA CORPORATION shareholders

Company details: InnoCan Pharma Corporation

InnoCan Pharma Corp.

926-5th Avenue SW

T2P 0N7, Calgary

+403-777-1519

http://www.innocanpharma.com

address InnoCan Pharma Corporation(INNO)

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
INNOCAN PHARMA CORPORATION	-1.23%	0.00%	-31.62%	-61.54%	25.87M
ELI LILLY AND COMPANY	+0.53%	-2.37%	+43.09%	+190.27%	930B
JOHNSON & JOHNSON	-0.41%	+6.98%	+48.72%	+26.86%	527B
ABBVIE INC.	-0.31%	-2.60%	+24.94%	+40.25%	379B
ROCHE HOLDING AG	+0.93%	+2.38%	+31.46%	+18.47%	371B
ASTRAZENECA PLC	+0.19%	-1.15%	+28.47%	+21.14%	292B
NOVARTIS AG	+0.98%	+1.37%	+29.42%	+35.03%	276B
MERCK & CO., INC.	-1.93%	-1.54%	+11.14%	-1.47%	270B
NOVO NORDISK A/S	+6.49%	+1.95%	-32.44%	-18.44%	268B
AMGEN INC.	+0.12%	+1.32%	+21.43%	+22.64%	178B
Average	+0.54%	+0.63%	+17.46%	+27.32%	349.1B
Weighted average by Cap.	+0.59%	+0.50%	+29.05%	+65.22%